In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussion regarding the numerous controversies that have enclosed flibanserin since the very beginning. This includes questions related to flibanserin's safety and efficacy and the validity of the clinical trials. Also included are philosophical considerations surrounding the diagnosis of hypoactive sexual desire disorder and pharmacological treatment of low libido. Based on the review of literature, authors judge flibanserin to be modestly effective and reasonably safe, and discuss the differences in philosophical perspectives with less definitive answers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00737-016-0693-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Neuropharmacology
January 2025
Department of Neuroscience, University of Minnesota, Minneapolis, MN, 55455, USA.
Hypoactive sexual desire disorder (HSDD) is the most reported sexual dysfunction among premenopausal women worldwide. Bremelanotide, trade name Vyleesi, has been approved by the United States Food and Drug Administration to treat HSDD. However, despite approval, very little is known about its neurobiological mechanism of action.
View Article and Find Full Text PDFImpact of a Single Session of Hybrid Carbon Dioxide 10600 Nanometer and 1540 Nanometer Laser With Platelet-Rich Plasma Treatment in the Genital Area to Treat Female Sexual Dysfunction: A Pilot Study.
Cureus
December 2024
Department of Aesthetic and Anti-Aging Medicine, Central Medica Quirurgica, Mazatlan, MEX.
Background Female sexual dysfunction (FSD) affects a significant portion of the female population, negatively impacting quality of life. New therapeutic approaches, such as the combination of laser therapy and platelet-rich plasma (PRP), are being explored as potential treatments to enhance sexual function in affected women. Methods This original study involved 23 women aged 37 to 72, all diagnosed with varying degrees of FSD (mild, moderate, severe).
View Article and Find Full Text PDFPsychological and sociodemographic factors associated with hypoactive sexual desire in Ecuadorian women.
Front Sociol
November 2024
Carrera de Ingeniería Industrial, Facultad de Ingenierías, Universidad Tecnológica Indoamérica, Ambato, Ecuador.
Introduction: Human sexuality is a multifaceted process, and sexual desire plays a central role in the triphasic model of the sexual response cycle, as proposed by Helen Singer Kaplan.
Methods: In this cross-sectional correlational study, we examined the relationship between various sociodemographic factors, such as age and motherhood, and sexual variables, including erotophobia, erotophilia, homophobia, and unconventional sex, with hypoactive sexual desire in women from Quito, Ecuador. The study sample comprised 421 women between the ages of 18 and 50, who were administered the Revised Sexual Opinion Survey and the Inhibited Sexual Desire Scale to assess their sexual attitudes and levels of desire.
Stress during early life influences brain development and can affect social, motor, and emotional processes. We describe a striking sex difference in the effects of early life stress (ELS), which produces anhedonia and anxiety-like behaviors in female adolescent mice, as reported previously, but repetitive behavioral pathology and social deficits in male adolescent mice. Notably, this parallels sex differences seen in the prevalence of psychiatric symptoms: depression and anxiety disorders are more common in girls and women, whereas neurodevelopmental disorders like autism spectrum disorder and Tourette syndrome are markedly more common in boys and men.
View Article and Find Full Text PDFSympathetic hypoactivity leads to hypocontractility of the corpus cavernosum in sickle cell mice: a mechanism contributing to priapism.
Int J Impot Res
November 2024
Laboratory of Pharmacology, São Francisco University Medical School, Bragança Paulista, SP, Brazil.
Priapism, a prevalent complication in sickle cell disease (SCD) patients, manifests as prolonged and painful erections unrelated to sexual arousal. The detailed mechanisms contributing to this condition, especially regarding sympathetic function in the corpus cavernosum that maintains penile flaccidity, remain to be elucidated. In this study, it was hypothesized that the pathways of the sympathetic nervous system would be down-regulated, thereby contributing to the development of ischemic priapism in sickle cell disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!